CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
浆细胞疾病病理生理学和治疗的最新进展
英文原题：Recent advances in the pathophysiology and treatment of plasma cell dyscrasias.
查看英文原题
Recent advances in the pathophysiology and treatment of plasma cell dyscrasias.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤是一种尚无法治愈的浆细胞恶性肿瘤。蛋白酶体抑制剂、免疫调节药物和单克隆抗体的应用改善了患者预后，但既往接受过三类药物治疗的骨髓瘤（TCE骨髓瘤）结局仍较差。如今，CAR-T 细胞疗法和双特异性抗体等新治疗选择进一步改善了预后，即使对TCE骨髓瘤患者亦如此。真正治愈仍具挑战，但目前认为功能性治愈是现实治疗目标；其定义是通过有利的免疫环境长期控制疾病并抑制微小残留病（MRD）。
展开英文摘要原文
Multiple myeloma is an incurable plasma cell malignancy. Its prognosis improved with the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, but outcomes for triple-class-exposed (TCE) myeloma remained poor.
New therapeutic options including CAR-T cell therapy and bispecific antibodies have now further improved prognosis, even in TCE myeloma. While true cure remains challenging, functional cure, defined as long-term disease control through a favorable immune environment suppressing minimal residual disease (MRD), is currently considered a realistic therapeutic goal.
论文信息
- 作者
- Suzuki K
- 单位
- Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-0003, Japan. kaz-suzuki@jikei.ac.jp.Japan
- 文献类型
- 综述
- 期刊
- International journal of hematology2026 Jul
- 原文标识
- PubMed 41615551 · DOI 10.1007/s12185-026-04166-6